GlobeStar Therapeutics Corporation GSTC
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0001 Day range 0.0001
0.0001 52-week range 0.0001
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 124.11K
- Vol
- 300.00K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.0001
- High
- 0.0001
2Y chart
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 30, 2025 | 1 year ago |
| RSI: Oversold | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 28, 2025 | 1 year ago |
| SMA: Bullish | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| SMA: Bullish | Mar 19, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 26, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 11, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| Jun 28, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Mar 11, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Jan 19, 2024 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 17, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| May 31, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
- Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials
- GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment
- Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment
- GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
- GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
- GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis
- GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign
- GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season
Your note
Sign in to keep a note on GSTC — it syncs with the Stock Master app.